Pathological fear and anxiety disorders, including post-traumatic stress disorder (PTSD), which are associated with exaggerated reactions to fearful stimuli and an inability to extinguish learned fear, underlie some of the most common and debilitating psychiatric disorders^[@CR1]^. The understanding of the neural circuitry and genetics underlying PTSD has rapidly progressed over recent years, and there is great interest in developing novel pharmacologic treatments based on these findings. Human neuroimaging and rodent models have implicated numerous cortical, subcortical, and midbrain regions in producing the symptoms observed in patients with PTSD (Fig. [1a](#Fig1){ref-type="fig"}). This disorder is frequently conceptualized as a memory disorder with dysregulated fear learning at the core of many of its signs and symptoms^[@CR2]^. Three of the most well studied and interconnected brain regions linked to PTSD symptoms are the amygdala, medial prefrontal cortex (mPFC), and hippocampus (HP). In PTSD, there is a failure of top-down cortical inhibition, leading to the reactivation of memories associated with trauma-related thoughts and feelings. Failure of top-down inhibition impairs the ability to extinguish fear^[@CR3]^, which is the active learning of a new non-threatening association. Thus, previously dangerous stimuli are no longer considered fearful. PTSD patients exhibit deficits in recall of extinction memory and display diminished activation of the mPFC and HP, which correlates with symptom severity and disrupted prefrontal-amygdala functional connectivity^[@CR3],[@CR4]^. In addition, recent evidence suggests that the neurobiological underpinnings related to altered cognition and mood are due to dysfunctions in the hippocampus and amygdala and their ability to regulate PFC top-down control^[@CR5]^.Fig. 1D-serine circuits, sympotom clusters, and the 'serine shuttle\'.**a** Diagram illustrating the human and rodent forebrain regions expressing high levels of serine racemase that are implicated in the major post-traumatic stress disorder symptom clusters. **b** Schematic representation of the serine shuttle in astrocytes and neurons. Glucose is transported from the blood into astrocytes by glucose transporter-1. Most brain [l]{.smallcaps}-serine is synthesized *de novo* from the glycolytic intermediate 3-phosphoglycerate, with phosphoglycerate 3-dehydrogenase being the committed step in astrocytic [l]{.smallcaps}-serine biosynthesis. [l]{.smallcaps}-serine is released from astrocytes by the alanine/serine/cysteine/threonine transporter-1 and is then taken up into neurons via currently unidentified transporter(s), where it is converted to [d]{.smallcaps}-serine by the enzyme serine racemase. Serine racemase is strongly inhibited by glycine, which competes for binding with [l]{.smallcaps}-serine. Serine racemase and [d]{.smallcaps}-serine are concentrated in dendrites and dendritic spines of glutamatergic and GABAergic neurons. [d]{.smallcaps}-serine is released from neurons, in part, by the alanine-serine-cysteine-1 transporter, where it binds to the glycine modulatory site on synaptic *N*-methyl-[d]{.smallcaps}-aspartate receptors. Glycine also regulates [d]{.smallcaps}-serine metabolism by affecting the efficiency of [d]{.smallcaps}-serine transport, as it is a high-affinity substrate of the alanine-serine-cysteine-1 transporter and can enhance the release of [d]{.smallcaps}-serine by amino acid hetero-exchange. [d]{.smallcaps}-serine can be eliminated from the synaptic space by either reuptake into astrocytes where it is catabolized by [d]{.smallcaps}-amino acid oxidase or via neuronal serine racemase. Asc-1 alanine-serine-cysteine-1, Slc7a10 solute carrier family 7 member 10, ASCT-1 alanine/serine/cysteine/threonine transporter-1 (Slc1a4; solute carrier Family 1 member 4), DAO [d]{.smallcaps}-amino acid oxidase, GLUT1 glucose transporter-1, GlyT-1 glycine transporter-1, mPFC medial prefrontal cortex, NMDAR *N*-methyl-[d]{.smallcaps}-aspartate receptor, PHGDH phosphoglycerate 3-dehydrogenase, *PSD* postsynaptic density, *SHMT* serine hydroxymethyltransferase, SR serine racemase, Some clipart in this figure were downloaded from <https://smart.servier.com>.

Pavlovian fear conditioning is one of the most widely used models for studying emotional memory and associative learning in rodents^[@CR6]^. The amygdala is a central hub in the emotional learning circuit, integrating sensory information from both cortical and subcortical brain regions related to the conditioning and extinction experience^[@CR7]^. Although multiple neurotransmitter systems can regulate extinction learning, many studies demonstrate the importance of NMDAR function in extinction learning using antagonists given either systemically or intracranially. In particular, NMDARs within the amygdala, mPFC, and hippocampus are essential for the acquisition and the extinction of fear memories and their associated physiologic symptoms^[@CR8]^. NMDARs require the binding of a co-agonist, [d]{.smallcaps}-serine or glycine, at the glycine modulator site (GMS) to function. [d]{.smallcaps}-serine is functionally a more potent activator of synaptic NMDARs than glycine^[@CR9]^, and mounting evidence suggests that it serves as the major NMDAR co-agonist in limbic brain regions implicated in neuropsychiatric disorders^[@CR10]^. Finally, clinical evidence suggests that D-cycloserine (DCS), a partial agonist at the NMDAR GMS, is modestly effective at treating patients with anxiety disorders, including PTSD, in conjunction with cognitive behavioral therapy^[@CR11],[@CR12]^. In the following sections, we discuss how the systems that regulate [d]{.smallcaps}-serine, a critical gatekeeper of NMDAR-dependent activation, could be targeted to improve the pharmacologic management of anxiety-related disorders where the desired outcomes are the facilitation of fear extinction, as well as mood and cognitive enhancement.

PTSD symptom domains and brain circuits {#Sec1}
=======================================

Intrusion symptoms in PTSD as defined in the DSM-5, are those in which the traumatic event is persistently re-experienced and can include recurring involuntary intrusive memories and physiological reactivity^[@CR13]^. Individuals with PTSD often display increased amygdala activity and decreased medial prefrontal cortex (mPFC) activity during symptom provocation studies when compared with controls^[@CR14]--[@CR17]^. This suggests that the reactivation of trauma-related memories in PTSD is associated with a failure of top-down cortical inhibition (e.g., from the mPFC) of the reactivation of trauma-related memories^[@CR18]^. Failure of top-down cortical inhibition might also underlie fear extinction impairments in PTSD^[@CR3]^.

In classical conditioning, fear conditioning occurs when a neutral cue (a tone or an image) is paired with an intrinsically aversive stimulus, such as electric shock, whereby subsequent presentations of the neutral cue induce a fear response. Fear extinction refers to the gradual reduction of the fear response to a conditioned stimulus when it fails to be reinforced^[@CR19]^. There is strong evidence that fear extinction involves the formation of a competing new memory that inhibits the fear response rather than an erasure of the original memory^[@CR19],[@CR20]^. However, fear memories may also weaken during recall through a process called reconsolidation^[@CR21]^. Although individuals with PTSD can encode new fear extinction memories, they do not retain them as well^[@CR3],[@CR22],[@CR23]^, suggesting a deficit in fear extinction retention that underlies PTSD symptoms. In PTSD subjects, the size and activity of the ventromedial PFC (vmPFC) is associated with the extent of fear extinction^[@CR24]^ and the changes to the functional connectivity between the vmPFC and the amygdala^[@CR25]^. These circuit changes could offer a mechanistic basis for the extinction retention impairments observed in PTSD subjects, since vmPFC-mediated inhibition of the amygdala is thought to be necessary for fear extinction^[@CR26]^.

Effortful avoidance of distressing trauma-related stimuli is another DSM-5 PTSD symptom domain^[@CR13]^. Imaging studies suggest that avoidance symptoms and fear circuit activation are closely linked, implicating the anterior cingulate and inferior frontal cortices, as well as hippocampus and amygdala. They also suggest that avoidance is integral to the observed PTSD fear extinction deficits^[@CR5]^. Since a cue or context that is avoided cannot be extinguished, behavioral therapy approaches for PTSD focus on decreasing avoidance behaviors.

Negative alterations in cognition and mood that begin or worsen after a traumatic event are another criterion in the DSM-5 PTSD diagnosis and include memory deficits and anhedonia symptomatology^[@CR13]^. Many of these alterations highly overlap with the symptoms of depression. Although preliminary, evidence points towards aberrations in limbic brain regions, particularly the hippocampus and amygdala, and their relationship with top-down PFC control. As the hippocampus is crucial for learning and memory processes, particularly declarative memory^[@CR27]^, hippocampal dysfunction has been proposed to account for PTSD memory deficits^[@CR28]^. The hippocampus is involved in the initial storage and integration of aspects of memory during retrieval. A substantial literature, including the largest brain imaging study of PTSD to date, demonstrates reduced hippocampal volume in PTSD patients^[@CR29],[@CR30]^. Individuals with PTSD also exhibit decreased hippocampal activity while taking part in a declarative memory task when compared with trauma-exposed controls without PTSD^[@CR31]^, as well as decreased hippocampal activity and a failure to recall extinction learning when taking part in a fear conditioning paradigm^[@CR3]^. Finally, extensive research also shows that individuals with PTSD have deficits in a number of executive function tasks^[@CR32]^.

[d]{.smallcaps}-Serine mediated nmdar activation and behavior {#Sec2}
=============================================================

As described above, the neural circuit abnormalities that contribute to the pathophysiology of PTSD are becoming more well defined. This section will focus on several interconnected limbic brain regions, including the amygdala, hippocampus, and mPFC, for which NMDAR-dependent activation is well-established in mediating behaviors in animal models that are relevant for the symptoms observed in PTSD patients (Table [1](#Tab1){ref-type="table"}). Specifically, we highlight what is known about [d]{.smallcaps}-serine dependent NMDAR activation, as both serine racemase (SR) and [d]{.smallcaps}-serine are enriched in excitatory and inhibitory neurons of these cortico-limbic brain regions^[@CR33]--[@CR35]^.Table 1Findings supporting the role of [d]{.smallcaps}-serine in fear conditioning and anxiety disorders.StudyMain findingMiserendino et al.^[@CR142]^Amygdalar NMDARs regulate conditioned fear acquisition in ratsWolosker et al.^[@CR143]^The purification, characterization and cloning of serine racemase, the enzyme that synthesizes [d]{.smallcaps}-serineRodrigues et al.^[@CR144]^The GluN2B subunit of amygdalar NMDARs regulate conditioned fear acquisition in ratsWalker et al.^[@CR145]^Intra-amygdala [d]{.smallcaps}-cycloserine facilitates the acquisition of conditioned fear in ratsRessler et al.^[@CR146]^In controlled trial, systemic [d]{.smallcaps}-cycloserine enhances fear extinction in humans with acrophobiaHeresco-Levy et al.^[@CR89]^In controlled trial, [d]{.smallcaps}-serine treatment reduces symptoms in humans with post-traumatic stress disorderBalu et al.^[@CR41]^Trace fear conditioning impairments in mice lacking serine racemase are restored by systemic treatment with [d]{.smallcaps}-serineBalu et al.^[@CR34]^Serine racemase and [d]{.smallcaps}-serine are localized to neurons, but not astrocytes, in mouse and human brainLi et al.^[@CR10]^Endogenous [d]{.smallcaps}-serine mediates NMDAR function during tonic activation in mouse amygdalaBalu et al.^[@CR33]^Serine racemase and [d]{.smallcaps}-serine are dynamically regulated by fear conditioning and extinction in the mouse amygdala*NMDARs* NMDA receptors.

NMDARs are unique compared to other ionotropic glutamate receptors because of their slow deactivation kinetics, high permeability to calcium, and their role as molecular coincidence detectors. Calcium influx through the NMDAR in neurons triggers a cascade of intracellular events that mediate local, acute functional synaptic plasticity and changes in gene expression that further influence synaptic plasticity^[@CR36]^. In addition to the binding of its agonist glutamate to the GluN2 subunit, NMDAR activation requires postsynaptic depolarization, which relieves the Mg^2+^ blockade of the channel, and the binding of either glycine or [d]{.smallcaps}-serine at the GMS on the GluN1 subunit^[@CR37],[@CR38]^. Although the co-agonists glycine and [d]{.smallcaps}-serine are present in the extracellular space^[@CR37]^, the GMS is not saturated in vivo^[@CR39]^. Importantly, [d]{.smallcaps}-serine is functionally more effective than glycine in activating NMDARs and is essential for NMDAR-dependent long-term potentiation (LTP) in numerous adult forebrain regions, including the hippocampus, amygdala, mPFC, and striatum^[@CR9],[@CR10],[@CR40]--[@CR44]^. It should be noted that glycine does serve a role in maintaining NMDAR-dependent plasticity in some adult synapses, such as in the thalamo-lateral amygdala^[@CR10]^ and medial perforant path-dentate gyrus synapses^[@CR9]^.

Individuals with PTSD display impairments in the extinction of traumatic memories. Although multiple neurotransmitter systems can regulate fear extinction learning, there is a very extensive literature demonstrating the importance of NMDAR function in extinction learning using antagonists given either systemically or intracranially. In particular, NMDARs within the amygdala and mPFC are essential for the acquisition and the extinction of fear memories and their associated physiologic symptoms^[@CR8]^. NMDAR function in the basolateral amygdala (BLA) is also critical for extinguishing conditioned fear responses, as many studies have shown that NMDAR antagonists delivered into the BLA impair extinction retrieval, while the infusion of DCS or [d]{.smallcaps}-serine into the BLA enhances extinction retrieval^[@CR11]^. The extinction of conditioned fear memory also depends on the mPFC, and in particular the infralimbic (IL) division, which sends very strong projections to the BLA^[@CR8],[@CR45]--[@CR48]^. Extinction training induces NMDAR-dependent plasticity and increases burst firing in IL neurons, which stabilizes fear extinction memory^[@CR49]^. Ligands of the NMDAR GMS, such as [d]{.smallcaps}-serine, are required for extinction learning. We have shown that SR levels are dynamically up-regulated in the hippocampus, amygdala, and mPFC after fear memory extinction^[@CR33]^. Mice that lack SR and have 90% lower [d]{.smallcaps}-serine, display impaired post-retrieval extinction of contextual fear memory that can be restored by [d]{.smallcaps}-serine administration, implicating a role for [d]{.smallcaps}-serine in the reconsolidation process^[@CR50]^. Exogenous [d]{.smallcaps}-serine or DCS administration facilitates the acquisition and retention of fear extinction^[@CR11],[@CR33],[@CR51]^, while [d]{.smallcaps}-serine also facilitates the extinction of drug seeking behavior^[@CR52]^. Clinical evidence also suggests that DCS is modestly effective at treating patients with anxiety disorders, including PTSD, in conjunction with cognitive behavioral therapy^[@CR11],[@CR12]^. In addition, a recent placebo-controlled, double-blind, three-day fear conditioning and delayed extinction fMRI study in healthy participants, found that DCS enhanced extinction consolidation, as reflected by reduced arousal ratings and activation of brain regions that mediate defensive reactions^[@CR53]^. Interestingly, findings in mice suggest that DCS may also serve as a precursor to [d]{.smallcaps}-serine in the brain^[@CR54]^. Finally, there is genetic evidence linking [d]{.smallcaps}-serine with PTSD. A single nucleotide polymorphism (SNP; [rs4523957](https://www.ncbi.nlm.nih.gov/snp/?term=rs4523957)) within the human serine racemase (*SRR*) gene previously associated with other disorders^[@CR55]--[@CR57]^, is a functional eQTL at the level of regulating SR mRNA expression in *post-mortem* human brain and is associated with PTSD^[@CR33]^ in a highly traumatized civilian population^[@CR58],[@CR59]^.

While extinction of classical fear conditioning (e.g., inhibitory and safety learning) relies on lower limbic implicit memory systems and processing of negative valence as a function of threat expectancy^[@CR60]^, fear extinction of hippocampus-dependent learning requires more complex, higher order associative learning processes^[@CR61]^. As such, episodic and semantic memory systems are predominantly prefrontal cortical and hippocampal/temporal, and thus likely engage different memory systems than those used for processing implicit, subcortical memory associations^[@CR62]^. Since NMDAR antagonism can produce discrete impairments in episodic and semantic memory^[@CR63]^, it is possible that increasing endogenous [d]{.smallcaps}-serine levels to increase NMDAR activity could facilitate the extinction of fear memories that engage higher-order processing.

Emerging literature describes the brain circuits engaged in mediating passive (freezing) and active avoidance strategies (e.g., escaping to a safe chamber) when an animals are presented with threat-associated stimuli^[@CR64]^. Rodent lesion studies indicate that passive freezing is mediated by signals transmitted from the lateral amygdala to the central amygdala and then to the periaqueductal gray^[@CR65]^. [d]{.smallcaps}-serine administration enhances memory extinction in an inhibitory avoidance task^[@CR66],[@CR67]^, potentially through increasing GluA2-containing AMPA receptor endocytosis^[@CR67]^.

Individuals with PTSD exhibit negative alterations in cognition and mood, such as anxiety and social withdrawal, that rely on proper NMDAR function and begin or worsen after a traumatic event. Numerous studies have demonstrated the importance of endogenous [d]{.smallcaps}-serine in mediating NMDAR activation for contextual and working memory in rodents^[@CR41],[@CR42],[@CR50],[@CR68]--[@CR70]^. Furthermore, endogenous [d]{.smallcaps}-serine is important for maintaining proper dendritic spine density and dendritic arborization of excitatory neurons and promotes the proliferation and survival of adult-born hippocampal neurons^[@CR41],[@CR71]--[@CR76]^. Preclinical studies indicate that [d]{.smallcaps}-serine or DCS administration can normalize behaviors used as models for anxiety and depression, as well as social memory and social interaction deficits, in genetic and pharmacologic rodent models^[@CR77]--[@CR80]^. It should be noted that small clinical studies suggest that NMDAR antagonism either with ketamine^[@CR81],[@CR82]^ or Ifenprodil (GluN2B-specififc)^[@CR83],[@CR84]^ had beneficial effects in treating depressive symptoms in PTSD patients and flashbacks of adolescent female PTSD patients with a history of abuse, respectively, through undefined mechanisms. Furthermore, the role of [d]{.smallcaps}-serine in neuroplasticity would presumably be beneficial to PTSD patients given that in rodents, stress, a key environmental risk factor for PTSD, reduces hippocampal volume, adult neurogenesis, dendritic complexity, and spine density^[@CR85]^. These findings in rodents comport with neuroimaging studies demonstrating that patients with PTSD have reduced volumes of the hippocampal and prefrontal brain regions^[@CR30],[@CR86],[@CR87]^. Finally, clinical studies demonstrate that GMS agonists, including [d]{.smallcaps}-serine, can improve cognition in healthy participants and patients with neuropsychiatric disorders^[@CR88]--[@CR91]^. It should be noted that the majority of these clinical studies had small sample sizes and included subjects primarily with schizophrenia, PTSD, or dementia. However, these proof-of-concept clinical trials do provide evidence supporting the use of NMDAR GMS agonists to improve mood and cognition.

[d]{.smallcaps}-Serine metabolism, uptake, and release {#Sec3}
======================================================

[d]{.smallcaps}-Serine production and localization {#Sec4}
--------------------------------------------------

[d]{.smallcaps}-Serine synthesis is carried out by SR, which catalyzes the racemization of [l]{.smallcaps}-serine into [d]{.smallcaps}-serine^[@CR92]^. A distinctive feature of SR is the catalysis of a parallel reaction consisting of the α, β-elimination of water from [l]{.smallcaps}-serine and production of pyruvate and ammonia, suggesting that SR also has a catabolic function^[@CR93]^. [d]{.smallcaps}-Serine and SR were initially thought to be exclusively present in astrocytes, leading to a series of studies that investigated the effects of "glial" [d]{.smallcaps}-serine^[@CR40],[@CR94],[@CR95]^. However, as recently reviewed in detail^[@CR96],[@CR97]^, studies purporting [d]{.smallcaps}-serine as a "gliotransmitter" lack the proper controls to ensure that the effects observed in NMDAR physiology are due to glial [d]{.smallcaps}-serine, such as the use of cell-selective SR-KO mice. The generation of more selective antibodies to SR and better techniques to detect [d]{.smallcaps}-serine^[@CR98]^, along with the use of SR-KO mice as controls for immunostaining^[@CR35],[@CR99],[@CR100]^ demonstrated that SR is preferentially expressed in neurons and [d]{.smallcaps}-serine having a neuronal origin. Cell-selective deletion of SR indicates that glutamatergic neurons are the primary site of [d]{.smallcaps}-serine synthesis^[@CR99],[@CR101]^, whereas the deletion of SR from astroglia had little effect on brain [d]{.smallcaps}-serine^[@CR99]^. NMDAR-dependent hippocampal plasticity is impaired in vitro and in vivo by the elimination of SR from glutamatergic neurons, while the deletion of astrocytic SR had no effect, indicating that astrocytic [d]{.smallcaps}-serine does not play a role in synaptic plasticity under normal conditions^[@CR99],[@CR102]^.

The serine shuttle {#Sec5}
------------------

A constant supply of [l]{.smallcaps}-serine is critical for [d]{.smallcaps}-serine synthesis, as the intracellular levels of [l]{.smallcaps}-serine (\~1 mM) are one order of magnitude below the apparent affinity of SR to [l]{.smallcaps}-serine^[@CR93]^. Although [l]{.smallcaps}-serine is a non-essential amino acid, most brain [l]{.smallcaps}-serine is synthesized from the glycolytic intermediate 3-phosphoglycerate by the sequential actions of three astrocyte-specific enzymes, phosphoglycerate dehydrogenase (Phgdh), phosphoserine aminotransferase 1 (Psat-1), and phosphoserine phosphatase (Psph)^[@CR103]^. Mutations in Phgdh, the committed step in astrocytic [l]{.smallcaps}-serine biosynthesis, cause microcephaly and severe neurodevelopmental deficits in humans attributable to deficits in brain [l]{.smallcaps}-serine^[@CR104],[@CR105]^. In agreement with human genetic studies, the astrocytic knockout of Phgdh decreases brain [l]{.smallcaps}-serine and [d]{.smallcaps}-serine in mice^[@CR106]^. This is associated with a decrease in the neuronal staining of [d]{.smallcaps}-serine^[@CR100]^, suggesting the existence of a "serine shuttle", whereby astrocytic [l]{.smallcaps}-serine shuttles to neurons to sustain neuronal synthesis of [d]{.smallcaps}-serine (Fig. [1b](#Fig1){ref-type="fig"}). Pharmacological inhibition of Phgdh in acute brain slices impairs NMDAR-dependent hippocampal functional plasticity, without changing basal neurotransmission^[@CR101]^, supporting the notion that the serine shuttle is essential for NMDAR activation^[@CR107]^.

The ASCT1 (Slc1a4) transporter mediates the export of [l]{.smallcaps}-serine and other neutral amino acids from astrocytes^[@CR69],[@CR108]^. Mice with targeted deletion of ASCT1 have lower brain [d]{.smallcaps}-serine, associated with a reduction in hippocampal volume, impairments in spatial memory, and motor dysfunction^[@CR69]^. Similar to patients with mutations in Phgdh, children with loss-of-function mutations in ASCT1 display microcephaly and severe neurodevelopmental deficits^[@CR109]--[@CR111]^, highlighting the role of astrocytic [l]{.smallcaps}-serine in neurodevelopment.

Hitherto unidentified transporters mediate the uptake of astrocyte-derived [l]{.smallcaps}-serine in neurons. Possible candidates include the Asc-1 (Slc7a10) neutral amino acid antiporter^[@CR112]^, system A (Slc38 family) transporters^[@CR113]^, or system L (Slc7 family) antiporters with broad specificity to zwitterionic amino acids^[@CR114]^. Once synthesized by SR, neuronal [d]{.smallcaps}-serine is released, at least in part, through Asc-1, which mediates [d]{.smallcaps}-serine efflux by exchange with extracellular neutral amino acids and/or facilitated diffusion^[@CR115],[@CR116]^. Targeted deletion or pharmacological inhibition of Asc-1 decreases the extracellular levels of [d]{.smallcaps}-serine^[@CR117]^ and impairs NMDAR-dependent synaptic plasticity in hippocampal Schaffer collaterals-CA1 synapses^[@CR116]^. Conversely, activation of the Asc-1 antiporter by increasing the levels of extracellular Asc-1 substrates enhances the [d]{.smallcaps}-serine release and promotes NMDAR synaptic activation^[@CR115]^. Asc-1 also uses glycine as substrate. Asc-1-KO mice display lower brain glycine and hyperekplexia due to the impairment of glycinergic inhibitory transmission that is preventable by administering glycine to the mice^[@CR112]^. These observations indicate that increasing the hetero-exchange activity of Asc-1 by selective substrates provides a strategy to increase the availability of NMDAR co-agonists.

Regulation of [d]{.smallcaps}-serine production at the postsynaptic site {#Sec6}
------------------------------------------------------------------------

Different from classical transmitters, [d]{.smallcaps}-serine appears to be mainly produced at postsynaptic sites. Subcellular fractionation demonstrated co-purification of SR with detergent-resistant postsynaptic density membranes^[@CR118]^. SR is localized to neurons^[@CR34],[@CR35]^, where it is enriched at dendritic spines^[@CR74]^. Furthermore, SR contains a PDZ binding region at its C-terminus and associates with several postsynaptic-enriched proteins, such as glutamate receptor interacting protein 1 (Grip-1)^[@CR119]^, discs large MAGUK scaffold protein 3 (SAP-102)^[@CR120]^, stargazin^[@CR120]^, discs large MAGUK scaffold protein 4 (PSD-95)^[@CR74],[@CR120]^, Disrupted in schizophrenia 1 (DISC1)^[@CR121]^, and protein interacting with PRKCA 1 (PICK1)^[@CR122]^. The proximity of SR to the postsynaptic sites provides a mechanism for local activation of synaptic NMDARs. Partial saturation of synaptic NMDARs by tonic [d]{.smallcaps}-serine release would allow immediate activation of NMDARs upon glutamate binding.

α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) stimulation has indirect effects on SR activity. In vitro evidence suggests that SR forms a quaternary complex with PSD-95, stargazin, and AMPARs, which partially inhibits the synthesis of [d]{.smallcaps}-serine. AMPAR activation leads to the dissociation of SR from stargazin and increases SR activity, providing a crosstalk between AMPAR and NMDAR activities that may play a role in synaptic homeostasis^[@CR120]^.

NMDAR activation leads to a cascade of events that inhibits SR activity by different mechanisms, providing a feedback regulation of NMDAR activity. NMDAR activation triggers the production of nitric oxide (NO) by nitric oxide synthase, leading to the S-nitrosylation of SR and inhibition of [d]{.smallcaps}-serine synthesis^[@CR123]^. NMDAR stimulation also elicits the translocation of SR from the cytosol to membranes and the cell nucleus, where the enzyme is mostly inactive^[@CR118],[@CR124]^. Feedback inhibition of SR likely serves to prevent NMDAR neurotoxicity under situations of increased neuronal activity. Conversely, blockade of NMDARs by chronic MK-801 administration increases SR expression in the brain^[@CR125]^, providing another connection between NMDAR activity and [d]{.smallcaps}-serine production.

SR levels are also regulated by the proteasomal system^[@CR126]^. DISC1 binds to and stabilizes SR by decreasing its degradation through the proteasome^[@CR121]^. DISC1 truncation segregates with schizophrenia and other psychiatric conditions in a Scottish family^[@CR127]^. Mice expressing mutant DISC1 exhibit lower SR and [d]{.smallcaps}-serine levels that are associated with behavioral alterations^[@CR121]^. In addition to feedback regulation, SR is strongly inhibited by glycine, which competes with [l]{.smallcaps}-serine for binding to SR^[@CR128],[@CR129]^. Injection of glycine leads to a decrease in the extracellular levels of [d]{.smallcaps}-serine in vivo, indicating their metabolism is connected^[@CR101]^. Inhibition of SR by glycine ensures that little [d]{.smallcaps}-serine will be produced in the brainstem and spinal cord, where glycine is the major inhibitory neurotransmitter^[@CR130]^. Glycine also regulates [d]{.smallcaps}-serine metabolism by affecting the efficiency of [d]{.smallcaps}-serine transport. Like [d]{.smallcaps}-serine, glycine is a high-affinity substrate of the Asc-1 transporter, and it enhances the release of [d]{.smallcaps}-serine via Asc-1 by amino acid hetero-exchange^[@CR101]^. The dual role of glycine in regulating [d]{.smallcaps}-serine metabolism is puzzling, and their regional variation and distinct half-lives provide a plethora of mechanisms to fine-tune NMDAR activity.

[d]{.smallcaps}-Serine catabolism {#Sec7}
---------------------------------

In the forebrain, [d]{.smallcaps}-serine has a half-life of 16.9 h^[@CR131]^, indicating slow metabolism. In comparison, metabolic labeling indicates that GABA and glutamate half-lives are around 30 min^[@CR132]^. Although [d]{.smallcaps}-serine can be degraded by [d]{.smallcaps}-amino acid oxidase (DAO) in peroxisomes, this enzyme is mostly restricted to the cerebellum, brainstem, and spinal cord^[@CR133]^. Mice expressing a catalytically-inactive DAO enzyme display no changes in cortical [d]{.smallcaps}-serine, indicating that DAO does not play a significant metabolic role in the adult forebrain^[@CR134]^. Human DAO expression is more widespread in forebrain regions, but the very low affinity for its cofactor FAD suggests this enzyme does not efficiently degrade [d]{.smallcaps}-serine in humans^[@CR135]^. Another possible catabolic route for [d]{.smallcaps}-serine is the SR enzyme itself, which can degrade [d]{.smallcaps}-serine into pyruvate and ammonia by the α,β-elimination reaction^[@CR93]^. However, although this pathway can play a role in limiting the build-up of [d]{.smallcaps}-serine in forebrain regions, the rate of conversion of [l]{.smallcaps}-serine into [d]{.smallcaps}-serine is faster than the α,β-elimination with [d]{.smallcaps}-serine^[@CR136]^, indicating that the [d]{.smallcaps}-serine synthesis is the preferential reaction of SR.

Transport mechanisms to remove [d]{.smallcaps}-serine from the synapse are not as efficient as with classical transmitters. [d]{.smallcaps}-serine reuptake systems are not stereoselective and display only moderate to low-affinity for the [d]{.smallcaps}-enantiomer^[@CR137]^. Therefore, we predict that [d]{.smallcaps}-serine will remain at the synapse for prolonged periods of time and will be functionally more effective than glycine, as powerful glycine transporters (e.g., glycine transporter-1; GlyT1), limit glycine access to synaptic NMDARs^[@CR39],[@CR138]^. In contrast to classical transmitters, neuronal depolarization has only modest effects on [d]{.smallcaps}-serine release^[@CR139]^. In this framework, we propose that [d]{.smallcaps}-serine works as an NMDAR gatekeeper that is tonically released at postsynaptic sites. The selective action of [d]{.smallcaps}-serine at NMDARs and its role in regulating behavior provides an opportunity to develop drugs that will gently affect NMDAR function by affecting the basal occupancy of the receptor.

Conclusions and future directions {#Sec8}
=================================

[d]{.smallcaps}-serine is a dynamic gatekeeper of NMDAR function in forebrain regions that are implicated in the pathophysiology of fear and anxiety-related disorders. We highlight the potential utility of [d]{.smallcaps}-serine or molecules that augment [d]{.smallcaps}-serine availability as a means to enhance extinction learning, as well as improving cognition and mood. The latter strategy could be accomplished by increasing release or blocking reuptake via the aforementioned transporters or inhibiting the breakdown of [d]{.smallcaps}-serine by DAO (Table [2](#Tab2){ref-type="table"}). While most of the properties of [d]{.smallcaps}-serine metabolism were characterized in the hippocampus and neocortex, it is likely that they are also conserved in the amygdala, as the expression of SR and other components of the serine shuttle are widespread throughout the brain. It will also be useful to test pharmacologic tools that augment [d]{.smallcaps}-serine mediated NMDAR-activation using rodent models of impaired extinction, which aim to recapitulate the aberrant extinction learning observed in PTSD patients^[@CR140]^. In addition, we propose the novel idea that [d]{.smallcaps}-serine is not a pre-synaptically released co-agonist, but a postsynaptically released "autocrine" molecule. Thus, the receptive neuron, not the glutamatergic input, determines NMDAR functionality. We hope this review helps to spur new lines of investigation into the mechanisms that regulate [d]{.smallcaps}-serine availability across brain regions and the relative contribution of GMS agonists at NMDARs on excitatory versus inhibitory neurons. We and others have shown strong [d]{.smallcaps}-serine immunoreactivity in several classes of GABAergic interneurons in the hippocampus, amygdala, cortex, and striatum^[@CR33]--[@CR35],[@CR74]^. Little is known about the regulation of SR in inhibitory neurons, but the postsynaptic localization of SR suggests that [d]{.smallcaps}-serine could also play an "autocrine" role in activating NMDARs on GABAergic neurons. Such findings could potentially help identify novel therapeutic targets to enhance [d]{.smallcaps}-serine mediated NMDAR function. A need for a deeper understanding of [d]{.smallcaps}-serine mediated NMDAR activation is highlighted by the modest success of DCS, a *partial agonist* at the GMS site, in augmenting exposure therapy outcomes in patients with anxiety disorders and PTSD^[@CR12],[@CR141]^.Table 2Putative novel pharmacologic strategies to increase [d]{.smallcaps}-serine mediated NMDA receptor transmission as a means to treat anxiety-related disorders.TargetFunctionPharmacologic manipulationAsc-1 (Slc7a10)[d]{.smallcaps}-Serine/amino acid exchangerActivator^[@CR116],[@CR147]^ASCT1 (Slc1a4)[d]{.smallcaps}-Serine/amino acid exchangerActivator^[@CR69]^DAAOEnzyme that breaks down [d]{.smallcaps}-serineInhibitor^[@CR148]--[@CR150]^Serine racemaseEnzyme that converts [l]{.smallcaps}-serine to [d]{.smallcaps}-serineActivator^[@CR151]^*Asc1* alanine-serine-cysteine-1 transporter, *ASCT1* alanine/serine/cysteine/threonine transporter-1, *DAAO*[d]{.smallcaps}-amino acid oxidase.
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